Vimian has resolved to issue and repurchase additional class D shares, class E1 2026 shares and class E2 2026 shares as part of its long-term incentive program 2026
At the Annual General Meeting of Vimian Group AB (publ) (“Vimian”) held on 29 April 2026, it was resolved to implement a long-term incentive program based on so-called hurdle shares and performance-based share awards (“LTIP 2026”). The Annual General Meeting authorized the Board of Directors to resolve upon a new issue of class D shares, class E1 2026 shares and class E2 2026 shares, and to repurchase the shares for further transfer to the participants in LTIP 2026. The Board of Directors previously, on 17 July 2026, resolved on a new issue, repurchase and transfer of a number of shares under LTIP 2026. The Board of Directors has today, in light of additional participants, based on the authorizations granted by the Annual General Meeting, resolved to carry out an additional new issue and subsequently repurchase a total of 252,699 shares, of which 159,871 class D shares, 46,414 class E1 2026 shares and 46,414 class E2 2026 shares.
As part of the implementation of LTIP 2026, 159,871 class D shares, 46,414 class E1 2026 shares and 46,414 class E2 2026 shares are issued to DNB Carnegie Investment Bank AB (“DNB Carnegie”) at a subscription price corresponding to the quota value per share (approximately SEK 0.00167). The share capital is thereby increased by SEK 421.41510. All issued shares will then, in accordance with the Board of Directors’ resolution, be repurchased by Vimian from DNB Carnegie at the same price for further transfer to the participants in LTIP 2026 in accordance with the terms and conditions resolved upon by the Annual General Meeting.
For further information, please contact:
Maria Dahllöf Tullberg
Head of IR, Communications & Sustainability
maria.tullberg@vimian.com
+46 73 626 88 86
About Vimian
Vimian is a global animal health company covering four essential and rapidly evolving areas: Specialty Pharma, MedTech, Veterinary Services and Diagnostics. At Vimian, we believe that every animal deserves the best available care. We bring pioneering and entrepreneurial businesses together to make the market’s most innovative offerings accessible to more animal health professionals and pet owners. Headquartered in Stockholm, Sweden, Vimian reaches veterinary clinics and laboratories in over 80 markets, has 1,300 employees and annual revenues of approximately EUR 425 million. For more information, please visit: www.vimian.com.